000282683 001__ 282683
000282683 005__ 20240229155044.0
000282683 0247_ $$2doi$$a10.2967/jnumed.123.266046
000282683 0247_ $$2pmid$$apmid:37678928
000282683 0247_ $$2ISSN$$a0097-9058
000282683 0247_ $$2ISSN$$a0022-3123
000282683 0247_ $$2ISSN$$a0161-5505
000282683 0247_ $$2ISSN$$a1535-5667
000282683 0247_ $$2ISSN$$a2159-662X
000282683 0247_ $$2altmetric$$aaltmetric:154063379
000282683 037__ $$aDKFZ-2023-01829
000282683 041__ $$aEnglish
000282683 082__ $$a610
000282683 1001_ $$0P:(DE-He78)1069938af8fd259742292e871ffe2c5c$$aKörber, Stefan$$b0$$eFirst author$$udkfz
000282683 245__ $$aImpact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.
000282683 260__ $$aNew York, NY$$bSoc.$$c2023
000282683 3367_ $$2DRIVER$$aarticle
000282683 3367_ $$2DataCite$$aOutput Types/Journal article
000282683 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1699347578_10420
000282683 3367_ $$2BibTeX$$aARTICLE
000282683 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282683 3367_ $$00$$2EndNote$$aJournal Article
000282683 500__ $$a#EA:E050# / 2023 Nov;64(11):1712-1720
000282683 520__ $$aSince the development of fibroblast activation protein-targeted radiopharmaceuticals, 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has been found to be suitable for detecting primary and metastatic lesions in many types of tumors. However, there is currently a lack of reliable data regarding the clinical impact of this family of probes. To address this gap, the present study aimed to analyze the clinical impact of 68Ga-FAPI PET/CT by examining a large cohort of patients with various tumors. Methods: In total, 226 patients (137 male and 89 female) were included in this retrospective analysis. Pancreatic cancer and head and neck cancers were the most common tumor types in this cohort. TNM stage and oncologic management were initially determined with gold standard imaging, and these results were compared with 68Ga-FAPI PET/CT. Changes were classified as major and minor. Results: For 42% of all patients, TNM stage was changed by 68Ga-FAPI PET/CT results. Most of these changes resulted in upstaging. A change in clinical management occurred in 117 of 226 patients. Although a major change in management occurred in only 12% of patients, there was a significant improvement in the ability to accurately plan radiation therapy. In general, the highest clinical impact of 68Ga-FAPI PET/CT imaging was found in patients with lung cancer, pancreatic cancer, and head and neck tumors. Conclusion: 68Ga-FAPI PET/CT is a promising imaging probe that has a significant impact on TNM stage and clinical management. 68Ga-FAPI PET/CT promises to be a crucial new technology that will improve on conventional radiologic imaging methods such as contrast-enhanced CT and contrast-enhanced MRI typically acquired for cancer staging.
000282683 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000282683 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000282683 650_7 $$2Other$$aFAPI
000282683 650_7 $$2Other$$aPET/CT
000282683 650_7 $$2Other$$amanagement
000282683 650_7 $$2Other$$aradiation therapy
000282683 650_7 $$2Other$$astaging
000282683 7001_ $$aRöhrich, Manuel$$b1
000282683 7001_ $$aWalkenbach, Leon$$b2
000282683 7001_ $$aLiermann, Jakob$$b3
000282683 7001_ $$aChoyke, Peter L$$b4
000282683 7001_ $$aFink, Christoph$$b5
000282683 7001_ $$aSchroeter, Cathrin$$b6
000282683 7001_ $$aSpektor, Anna-Maria$$b7
000282683 7001_ $$0P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc$$aHerfarth, Klaus$$b8
000282683 7001_ $$0P:(DE-He78)51635089578f68fc9efdb61e6a760b64$$aWalle, Thomas$$b9$$udkfz
000282683 7001_ $$aCalais, Jeremie$$b10
000282683 7001_ $$aKauczor, Hans-Ulrich$$b11
000282683 7001_ $$aJaeger, Dirk$$b12
000282683 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b13$$udkfz
000282683 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b14$$udkfz
000282683 7001_ $$aGiesel, Frederik L$$b15
000282683 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.123.266046$$gp. jnumed.123.266046 -$$n11$$p1712-1720$$tJournal of nuclear medicine$$v64$$x0097-9058$$y2023
000282683 909CO $$ooai:inrepo02.dkfz.de:282683$$pVDB
000282683 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1069938af8fd259742292e871ffe2c5c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000282683 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000282683 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51635089578f68fc9efdb61e6a760b64$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000282683 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000282683 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000282683 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000282683 9141_ $$y2023
000282683 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-19
000282683 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-19
000282683 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-19
000282683 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2022$$d2023-10-24
000282683 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000282683 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000282683 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000282683 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000282683 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000282683 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000282683 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000282683 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000282683 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2022$$d2023-10-24
000282683 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000282683 9201_ $$0I:(DE-He78)F230-20160331$$kF230$$lKKE Virotherapie$$x1
000282683 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000282683 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x3
000282683 9200_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000282683 980__ $$ajournal
000282683 980__ $$aVDB
000282683 980__ $$aI:(DE-He78)E050-20160331
000282683 980__ $$aI:(DE-He78)F230-20160331
000282683 980__ $$aI:(DE-He78)HD01-20160331
000282683 980__ $$aI:(DE-He78)E060-20160331
000282683 980__ $$aUNRESTRICTED